Difference between revisions of "Tamibarotene (Amnoid)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=571791 NCI Drug Dictionary]: An orally active, synthetic retinoid, developed...") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
Line 5: | Line 5: | ||
==[[Acute promyelocytic leukemia]]== | ==[[Acute promyelocytic leukemia]]== | ||
− | # Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov;171(4):471-7. Epub 2015 Jul 24. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13607/full link to original article] [ | + | # Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov;171(4):471-7. Epub 2015 Jul 24. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13607/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26205361 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] |
Revision as of 02:19, 2 December 2016
Mechanism of action
From the NCI Drug Dictionary: An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.
Preliminary data
Acute promyelocytic leukemia
- Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov;171(4):471-7. Epub 2015 Jul 24. link to original article PubMed